Literature DB >> 17639498

cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy.

Chi-Ming Liu1, Yi-Ching Lo, Bin-Nan Wu, Wen-Jeng Wu, Yii-Her Chou, Chun-Hsiung Huang, Li-Mei An, Ing-Jun Chen.   

Abstract

BACKGROUND: Soluble guanylyl cyclase (sGC)/cyclic guanosine monophosphate (cGMP)/protein kinase G (PKG) and Rho kinase (ROCK2) pathways are important in the regulation of prostate smooth muscle tone. This study is aimed to examine the relaxation activities of a sGC activator and PDE5A/ROCK2 inhibitor KMUP-1 in rat prostate and associated anti-proliferation activity in human prostatic epithelial cells.
METHODS: The action characteristics of KMUP-1 were identified by isometric tension measurement, receptor binding assay, Western blotting and radioimmunoassay in rat prostate. Anti-proliferation activity of KMUP-1 in human prostatic epithelial PZ-HPV-7 cells was identified using flow cytometry and real time QRT-PCR.
RESULTS: KMUP-1 inhibited phenylephrine-induced contractility in a concentration-dependent manner. KMUP-1 possessed potent alpha(1A/)alpha(1D)-adrenoceptor binding inhibition activity, increased cAMP/cGMP levels and increased the expression of sGC, PKG, and PKA protein in rat prostate. Moreover, KMUP-1 inhibited phenylephrine-induced ROCK2 expression. KMUP-1 inhibited cell growth, arrested the cell cycle at G(0)/G(1) phase and increased the expression of p21 in PZ-HPV-7 cells.
CONCLUSIONS: These results broaden our knowledge of sGC/cGMP/PKG and ROCK2 regulation on the relaxation and proliferation of prostate, which may help in the design of benign prostate hyperplasia (BPH) therapies that target these signaling pathways. KMUP-1 possesses the potential benefit in the treatment of BPH by its alpha(1A/)alpha(1D)-adrenoceptor blockade, sGC activation, inhibition of PDE5A and ROCK2 and p21 protein enhancement, leading to attenuation of the smooth muscle tone and the proliferation of epithelial PZ-HPV-7 cells. The synergistic contribution of these pathways by KMUP-1 may benefit BPH patients with lower urinary tract symptoms. 2007 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17639498     DOI: 10.1002/pros.20634

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Actions of KMUP-1, a xanthine and piperazine derivative, on voltage-gated Na(+) and Ca(2+) -activated K(+) currents in GH3 pituitary tumour cells.

Authors:  Yi-Ching Lo; Yu-Ting Tseng; Chi-Ming Liu; Bin-Nan Wu; Sheng-Nan Wu
Journal:  Br J Pharmacol       Date:  2015-10-25       Impact factor: 8.739

2.  The xanthine derivative KMUP-1 inhibits models of pulmonary artery hypertension via increased NO and cGMP-dependent inhibition of RhoA/Rho kinase.

Authors:  Hui-Hsuan Chung; Zen-Kong Dai; Bin-Nan Wu; Jwu-Lai Yeh; Chee-Yin Chai; Koung-Shing Chu; Chung-Pin Liu; Ing-Jun Chen
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

4.  Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.

Authors:  Xinhua Zhang; Ning Zang; Yu Wei; Jin Yin; Ruobing Teng; Allen Seftel; Michael E Disanto
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-25       Impact factor: 4.310

5.  KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways.

Authors:  Jwu-Lai Yeh; Jong-Hau Hsu; Ping-Ju Wu; Shu-Fen Liou; Chung-Pin Liu; Ing-Jun Chen; Bin-Nan Wu; Zen-Kong Dai; Jiunn-Ren Wu
Journal:  Br J Pharmacol       Date:  2010-02-02       Impact factor: 8.739

6.  Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator.

Authors:  Irina V Zabbarova; Youko Ikeda; Mark G Kozlowski; Pradeep Tyagi; Lori A Birder; Basu Chakrabarty; Subashan Kpg Perera; Rajiv Dhir; Adam C Straub; Peter Sandner; Karl-Erik Andersson; Marcus J Drake; Christopher H Fry; Anthony J Kanai
Journal:  J Pathol       Date:  2022-02-15       Impact factor: 9.883

7.  Benign prostatic hyperplasia: from bench to clinic.

Authors:  Tag Keun Yoo; Hee Ju Cho
Journal:  Korean J Urol       Date:  2012-03-19

8.  Histone demethylase JMJD6 regulates cellular migration and proliferation in adipose-derived mesenchymal stem cells.

Authors:  Chongyang Shen; Qingli Quan; Chuan Yang; Yueqiang Wen; Hong Li
Journal:  Stem Cell Res Ther       Date:  2018-08-09       Impact factor: 6.832

9.  Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 + T cells in benign prostatic hyperplasia.

Authors:  Song Jin; Peng Xiang; Jie Liu; Yang Yang; Shuai Hu; Jindong Sheng; Qun He; Wei Yu; Wenke Han; Jie Jin; Jing Peng
Journal:  Prostate       Date:  2019-04-08       Impact factor: 4.104

10.  KMUP-1 suppresses RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss: roles of MAPKs, Akt, NF-κB and calcium/calcineurin/NFATc1 pathways.

Authors:  Shu-Fen Liou; Jong-Hau Hsu; I-Ling Lin; Mei-Ling Ho; Pei-Chuan Hsu; Li-Wen Chen; Ing-Jun Chen; Jwu-Lai Yeh
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.